Congestion in acute heart failure syndromes: Importance of early recognition and treatment

Reviews in Cardiovascular Medicine

Volumn 7, Issue 2, 2006, Pages 69-74

  De Luca, Leonardo ^a   Abraham, William T ^b   Fonarow, Gregg C ^c   Gheorghiade, Mihai ^d  

^a EUROPEAN HOSPITAL   (Italy)

^b OHIO STATE UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Acute heart failure syndromes; Diuretics; Left ventricular filling pressure; Pulmonary capillary wedge pressure; Pulmonary congestion

Indexed keywords

ALDOSTERONE ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LOOP DIURETIC AGENT;

ACUTE HEART FAILURE; CLINICAL FEATURE; CONGESTIVE CARDIOMYOPATHY; DISEASE EXACERBATION; DRUG TARGETING; ELECTROLYTE DISTURBANCE; ENDOCRINE DISEASE; HEART LEFT VENTRICLE FILLING PRESSURE; HEART OUTPUT; HEMODYNAMICS; HOSPITAL ADMISSION; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; HYPOTENSION; KIDNEY DISEASE; LUNG CONGESTION; MORBIDITY; MORTALITY; PREDICTION; REVIEW; SYMPTOMATOLOGY;

ACUTE DISEASE; DIURETICS; EARLY DIAGNOSIS; EDEMA, CARDIAC; HEART FAILURE; HEART FAILURE, CONGESTIVE; HUMANS; PULMONARY EDEMA; PULMONARY WEDGE PRESSURE; SYNDROME; VENTRICULAR FUNCTION, LEFT;

EID: 33746105793     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Gheorghiade M, Zannad F, Sopko G, et al. Acute heart failure syndromes: current state and framework for future research. Circulation. 2005;112:3958-3968.
2. Kozak LJ, Owings MF, Hall MJ. National Hospital Discharge Survey: 2002 annual summary with detailed diagnosis and procedure data. Vital Health Stat 13. 2005;1-199.
3. Thom T, Haase N, Rosamond W, et al. Heart Disease and Stroke Statistics - 2006 Update. A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Available at: http://circ.ahajournals.org/cgi/reprint/CIRCULATIONAHA.105.171600v1. Accessed January 17, 2006.
4. Cleland JG, Swedberg K, Follath F, et al. The EuroHeart Failure survey programme - a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J. 2003;24: 442-463.
5. Cuffe MS, Califf RM, Adams KFJ, et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA. 2002;287:1541-1547.
6. Gattis WA, O'Connor CM. Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure. Am J Cardiol. 2004;93(suppl):74B-76B.
7. Gheorghiade M, Gattis WA, O'Connor CM, et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA. 2004;291:1963-1971.
8. Adams KF Jr, Fonarow GC, Emerman CL, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J. 2005;149:209-216.
9. Fonarow GC, Abraham WT, Albert NM, et al. Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF): rationale and design. Am Heart J. 2004;148:43-51.
10. Gattis WA, O'Connor CM, Gallup DS, et al. Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial. J Am Coll Cardiol. 2004;43:1534-1541.
11. Lucas C, Johnson W, Hamilton MA, et al. Freedom from congestion predicts good survival despite previous class IV symptoms of heart failure. Am Heart J. 2000;140:840-847.
12. Drazner MH, Rame JE, Stevenson LW, Dries DL. Prognostic importance of elevated jugular venous pressure and a third heart sound in patients with heart failure. N Engl J Med. 2001; 345:574-581.
13. Fonarow GC, Stevenson LW, Steimle AE, et al. Persistently high left ventricular filling pressures predict mortality despite angiotensin converting enzyme inhibition in advanced heart failure [abstract 2624]. Circulation. 1994;90(4 pt 2):1-488.
14. The ESCAPE Investigators and ESCAPE Study Coordinators. Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. JAMA. 2005;294:1625-1633.
15. Adamson PB, Magalski A, Braunschweig F, et al. Ongoing right ventricular hemodynamics in heart failure: clinical value of measurements derived from an implantable monitoring system. J Am Coll Cardiol. 2003;41:565-571.
16. Mahdyoon H, Klein R, Eyler W, et al. Radiographic pulmonary congestion in end-stage congestive heart failure. Am J Cardiol. 1989; 63:625-627.
17. Stevenson LW, Perloff JK. The limited reliability of physical signs for estimating hemodynamics in chronic heart failure. JAMA. 1989;261: 884-888.
18. Publication Committee for the VMAC Investigators. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA. 2002;287:1531-1540.
19. Fonarow GC. The Acute Decompensated Heart Failure National Registry (ADHERE): opportunities to improve care of patients hospitalized with acute decompensated heart failure. Rev Cardiovasc Med. 2003;4(suppl 7):S21-S30.
20. Gheorghiade M, De Luca L, Fonarow GC, et al. Pathophysiologic targets in the early phase of acute heart failure syndromes. Am J Cardiol. 2005;96:11G-17G.
21. DiDomenico RJ, Park HY, Southworth MR, et al. Guidelines for acute decompensated heart failure treatment. Ann Pharmacother. 2004;38: 649-660.
22. Nieminen MS, Bohm M, Cowie MR, et al for the ESC Committe for Practice Guideline (CPG). Executive summary of the guidelines on the diagnosis and treatment of acute heart failure. The Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J. 2005;26:384-416.
23. Cotter G, Weissgarten J, Metzkor E, et al. Increased toxicity of high-dose furosemide versus low-dose dopamine in the treatment of refractory congestive heart failure. Clin Pharmacol Ther. 1997;62:187-193.
24. Francis GS, Siegel RM, Goldsmith SR, et al. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis. Ann Intern Med. 1985;103:1-6.
25. Francis GS, Benedict C, Johnstone DE, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation. 1990;82:1724-1729.
26. 1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation. 2002;105:1348-1353.
27. Ikram H, Chan W, Espiner EA, Nicholls MG. Haemodynamic and hormone responses to acute and chronic furosemide therapy in congestive heart failure. Clin Sci. 1980;59: 443-449.
28. Cooper HA, Dries DL, Davis CE, et al. Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation. 1999; 100:1311-1315.
29. Costanzo MR, Heywood JT, DeMarco T, et al. Impact of renal insufficiency and chronic diuretic therapy on outcome and resource utilization in patients with acute decompensated heart failure [abstract 1069-114]. J Am Coll Cardiol. 2004;43(suppl A): 180A.
30. Domanski M, Norman J, Pitt B, et al. Diuretic use, progressive heart failure, and death in patients in the studies of left ventricular dysfunction (SOLVD). J Am Coll Cardiol. 2003;42: 705-708.
31. Emerman CL, DeMarco T, Costanzo MR, Peacock WF. Impact of intravenous diuretics on the outcomes of patients hospitalized with acute decompensated heart failure: insights from the ADHERE Registry [abstract]. J Card Fail. 2004;10(suppl 4):S116.
32. Mehta RL, Pascual MT, Soroko S, Chertow GM. Diuretics, mortality, and nonrecovery of renal function in acute renal failure. JAMA. 2002; 288:2547-2553.
33. Neuberg GW, Miller AB, O'Connor CM, et al. Diuretic resistance predicts mortality in patients with advanced heart failure. Am Heart J. 2002;144:31-38.
34. Ahmed A, Husain A, Love TE, et al. Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods. Eur Heart J. 2006. In press.
35. Remes J, Miettinen H, Reunanen A, Pyörälä K. Validity of clinical diagnosis of heart failure in primary health care. Eur Heart J. 1991;12: 315-321.
36. Marcus GM, Gerber IL, McKeown BH, et al. Association between phonocardiographic third and fourth heart sounds and objective measures of left ventricular function. JAMA. 2005;293:2238-2244.
37. Felker GM, Cuculich PS, Gheorghiade M. The valsalva maneuver: a bedside "biomarker" for heart failure. Am J Med. 2006;119:117-122.
38. Chakko S, Woska D, Martinez H, et al. Clinical, radiographic, and hemodynamic correlations in chronic congestive heart failure: conflicting results may lead to inappropriate care. Am J Med. 1991;90:353-359.
39. Capomolla S, Ceresa M, Pinna G, et al. Echo-Doppler and clinical evaluations to define hemodynamic profile in patients with chronic heart failure: accuracy and influence on therapeutic management. Eur J Heart Fail. 2005;7:624-630.
40. Logeart D, Thabut G, Jourdain P, et al. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. J Am Coll Cardiol. 2004;43:635-641.
41. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347:161-167.
42. Gegenhuber A, Mueller T, Dieplinger B, et al. Plasma B-type natriuretic peptide in patients with pleural effusions: preliminary observations. Chest. 2005;128:1003-1009.
43. Wu AH, Smith A, Apple FS. Optimum blood collection intervals for B-type natriuretic peptide testing in patients with heart failure. Am J Cardiol. 2004;93:1562-1563.
44. Wu AH, Smith A, Wieczorek S, et al. Biological variation for N-terminal pro- and B-type natriuretic peptides and implications for therapeutic monitoring of patients with congestive heart failure. Am J Cardiol. 2003;92:628-631.
45. Yu CM, Wang L, Chan E, et al. Intrathoracic impedance monitoring in patients with heart failure: correlation with fluid status and feasibility of early warning preceding hospitalization. Circulation. 2005;112:841-848.